To summarize the applications of data-intelligence technology in diagnosing lysosomal storage disease(LSD), analyze their opportunities and challenges in clinical practice as well as their development trends, and provide insights and recommendations for advancing digitally driven auxiliary diagnostic technologies.

To review the randomized controlled trials (RCTs) at home and abroad on digital intelligence (DI)-driven rehabilitation in patients of neuromuscular disease, compare the effects of DI-driven rehabilitation with traditional rehabilitation, summarize the special needs and challenges faced by patients in rehabilitation of rare neuromuscular diseases, and provide evidence for the development and quality improvement of rehabilitation for rare neuromuscular diseases.

To provide references to and give suggestions to the development and optimiza-tion of Digital Intelligence (DI) technology in management of non-hospitalized patients by systematical review the application of digital technology in non-hospital settings.

Since its establishment in 2016, the National Rare Diseases Registry System of China (NRDRS) has accumulated valuable case data and bio-specimen for basic and clinical research on rare diseases in China. However, the emerging challenges in clinical diagnosis and treatment of rare diseases make it unable for data and resource platform to fully meet the diversified needs. Under this backdrop, we have developed a protocol to optimize and upgrade the system based on the core functions of the NRDRS platform. The goal is to leverage intelligent digital technologies to transform NRDRS into a new platform integrating multimodal data and auxiliary diagnostic and treatment functions. It is specified as the development and construction of "one platform and four intelligent tools." Currently, we have upgraded and developed NRDRS platform, intelligent tool for genotype-phenotype analysis of rare diseases, AI-assisted diagnostic tool for rare diseases, remote multidisciplinary diagnosis and teaching tool for rare diseases, drug screening and validation tool for rare diseases. The next step will focus on the promotion of the application of these tools in clinical settings in order to address the issue of severe imbalance in the allocation of resources for the diagnosis and treatment of rare diseases. This article provides an overview of the digital and intelligent upgrades of the NRDRS, the trials in applications in clinical settings, and direction in the future.

Trigeminal neuralgia is characterized by intense pain in the sensory distribution area of the trigeminal nerve. It can be triggered by non-noxious stimuli such as brushing teeth and washing face. At present, the treatment of trigeminal neuralgia mainly includes oral drugs and surgical treatments. A 92-year-old patient with trigeminal neuralgia was reported. The pain could not be alleviated because the patient was unable to tolerate the side effects of drugs and surgical treatment. Taking into account the onset time and the duration of the curative effect, botulinum toxin type A was combined with cobrotoxin for the treatment of the patient. As a result, the pain symptoms were rapidly alleviated and remained in a relieved state for 8 months. The clinical characteristics of this patient were summarized in this article, and the possible synergistic mechanisms of action of the 2 drugs were discussed. The ultimate objective is to furnish a broader spectrum of alternatives and references for clinical practice.

Objective:Committee of Minimally Invasive Cardiovascular Surgery(CMICS) conducts an annual summary of minimally invasive cardiovascular surgery procedures performed throughout the country, which includes a comprehensive survey of the total number of minimally invasive procedures by region and the distribution of minimally invasive procedures by hospital. Since CMICS first published the 2018-2019 China Minimally Invasive Cardiovascular Surgery Data White Paper in 2020, the report has received great attention from peers within and outside the industry. In this statistical report, CMICS will focus on publishing the data related to minimally invasive cardiovascular surgery in China from 2021 to 2023 for reference and use by industry peers.

Rare diseases are characterized by very low incidence and prevalence rates,complex genetic mechanisms,and diverse clinical phenotypes,posing significant diagnostic and therapeutic challenges in clinical research.In principle,the design of clinical research protocols for rare diseases does not differ significantly from general clinical research.However,the difficulties mainly stem from the unique characteristics of rare diseases,which amplify the challenges and limitations inherent in general clinical research.These challenges typically involve five aspects:data collection,data management,technical methods,ethical regulations,and patient engagement.However,with the rapid development of digital technologies such as information technology,artificial intelligence(AI),and blockchain,particularly in the innovative applications of data collection,storage,analysis,sharing,and management,new opportunities have emerged for the implementation and optimization of rare disease clinical research.Strategies for conducting rare disease clinical research using digital technologies are often applied to rare disease clinical research and patient management based on digitalized registration platforms,the development of AI-driven diagnostic aids to improve the accuracy of rare disease diagnosis,the use of digital technologies for decentralized rare disease clinical research,and the promotion of data fusion from multiple sources and modalities.However,during the application process,new challenges have gradually been identified.Despite of many challenges that still exist in terms of data privacy,algorithmic fairness,and ethical norms,with the continuous maturation of technology and the improvement of ethical frameworks,digitally-intelligent-driven clinical research on rare diseases remains promising.

Rare diseases are characterized by very low incidence and prevalence rates,complex genetic mechanisms,and diverse clinical phenotypes,posing significant diagnostic and therapeutic challenges in clinical research.In principle,the design of clinical research protocols for rare diseases does not differ significantly from general clinical research.However,the difficulties mainly stem from the unique characteristics of rare diseases,which amplify the challenges and limitations inherent in general clinical research.These challenges typically involve five aspects:data collection,data management,technical methods,ethical regulations,and patient engagement.However,with the rapid development of digital technologies such as information technology,artificial intelligence(AI),and blockchain,particularly in the innovative applications of data collection,storage,analysis,sharing,and management,new opportunities have emerged for the implementation and optimization of rare disease clinical research.Strategies for conducting rare disease clinical research using digital technologies are often applied to rare disease clinical research and patient management based on digitalized registration platforms,the development of AI-driven diagnostic aids to improve the accuracy of rare disease diagnosis,the use of digital technologies for decentralized rare disease clinical research,and the promotion of data fusion from multiple sources and modalities.However,during the application process,new challenges have gradually been identified.Despite of many challenges that still exist in terms of data privacy,algorithmic fairness,and ethical norms,with the continuous maturation of technology and the improvement of ethical frameworks,digitally-intelligent-driven clinical research on rare diseases remains promising.

Objective:Committee of Minimally Invasive Cardiovascular Surgery(CMICS) conducts an annual summary of minimally invasive cardiovascular surgery procedures performed throughout the country, which includes a comprehensive survey of the total number of minimally invasive procedures by region and the distribution of minimally invasive procedures by hospital. Since CMICS first published the 2018-2019 China Minimally Invasive Cardiovascular Surgery Data White Paper in 2020, the report has received great attention from peers within and outside the industry. In this statistical report, CMICS will focus on publishing the data related to minimally invasive cardiovascular surgery in China from 2021 to 2023 for reference and use by industry peers.

Trigeminal neuralgia is characterized by intense pain in the sensory distribution area of the trigeminal nerve. It can be triggered by non-noxious stimuli such as brushing teeth and washing face. At present, the treatment of trigeminal neuralgia mainly includes oral drugs and surgical treatments. A 92-year-old patient with trigeminal neuralgia was reported. The pain could not be alleviated because the patient was unable to tolerate the side effects of drugs and surgical treatment. Taking into account the onset time and the duration of the curative effect, botulinum toxin type A was combined with cobrotoxin for the treatment of the patient. As a result, the pain symptoms were rapidly alleviated and remained in a relieved state for 8 months. The clinical characteristics of this patient were summarized in this article, and the possible synergistic mechanisms of action of the 2 drugs were discussed. The ultimate objective is to furnish a broader spectrum of alternatives and references for clinical practice.